Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that beta-1 receptor blockade (ß1-RB) attenuates extracellular
matrix (ECM) degradation and progressive adverse Left Ventricular (LV) remodeling and failure
in the volume overload of mitral regurgitation (MR). Patients without coronary artery disease
and moderate MR, as assessed by color/flow Doppler echocardiography, will be randomized to
ß1-RB vs. placebo to address the following aims:
*Aim 1: Establish whether ß1-RB attenuates adverse LV remodeling compared to placebo in
patients with non-surgical, chronic MR. Using 3-dimensional magnetic resonance imaging (MRI)
and tissue tagging, LV function and geometry will be assessed at baseline and every 6 months
for up to 2 years.
Aim 2: Determine whether indices of inflammation correlate with degree of LV remodeling and
whether ß1-RB decrease indices of inflammation and collagen turnover. At the time of MRI,
blood samples for collagen breakdown products, matrix metalloproteinase (MMP) activity, and
markers of excess production of reactive inflammatory species (RIS) will be obtained and
related to changes in LV remodeling defined by serial 3-dimensional MRI and tissue tagging.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborators:
AstraZeneca National Heart, Lung, and Blood Institute (NHLBI)